Targeting PD-1/PD-L1 in lung cancer: current perspectives

María González-Cao,1 Niki Karachaliou,1 Santiago Viteri,1 Daniela Morales-Espinosa,1 Cristina Teixidó,2 Jesús Sánchez Ruiz,3 Miquel Ángel Molina-Vila,2 Mariacarmela Santarpia,4 Rafael Rosell1,2,5,61Translational Cancer Research Unit,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	González-Cao M, Karachaliou N, Viteri S, Morales-Espinosa D, Teixidó C, Sánchez Ruiz J, Molina-Vila MÁ, Santarpia M, Rosell R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/53cb1147aa7d460ab1939a5683d7eba4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:53cb1147aa7d460ab1939a5683d7eba4
record_format	dspace
spelling	oai:doaj.org-article:53cb1147aa7d460ab1939a5683d7eba42021-12-02T01:38:27ZTargeting PD-1/PD-L1 in lung cancer: current perspectives1179-2728https://doaj.org/article/53cb1147aa7d460ab1939a5683d7eba42015-07-01T00:00:00Zhttp://www.dovepress.com/targeting-pd-1pd-l1-in-lung-cancer-current-perspectives-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728María González-Cao,1 Niki Karachaliou,1 Santiago Viteri,1 Daniela Morales-Espinosa,1 Cristina Teixidó,2 Jesús Sánchez Ruiz,3 Miquel Ángel Molina-Vila,2 Mariacarmela Santarpia,4 Rafael Rosell1,2,5,61Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain; 2Pangaea Biotech SL, Barcelona, Spain; 3Centro Nacional de Investigación Oncología (CNIO), Madrid, Spain; 4Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy; 5Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain; 6Fundación Molecular Oncology Research, Barcelona, SpainAbstract: Increased understanding of tumor immunology has led to the development of effective immunotherapy treatments. One of the most important advances in this field has been due to pharmacological design of antibodies against immune checkpoint inhibitors. Anti-PD-1/PD-L1 antibodies are currently in advanced phases of clinical development for several tumors, including lung cancer. Results from Phase I–III trials with anti-PD-1/PD-L1 antibodies in non-small-cell lung cancer have demonstrated response rates of around 20% (range, 16%–50%). More importantly, responses are long-lasting (median duration of response, 18 months) and fast (50% of responses are detected at time of first tumor evaluation) with very low grade 3–4 toxicity (less than 5%). Recently, the anti-PD-1 antibody pembrolizumab received US Food and Drug Administration (FDA) breakthrough therapy designation for treatment of non-small-cell lung cancer, supported by data from a Phase Ib trial. Another anti-PD-1 antibody, nivolumab, has also been approved for lung cancer based on survival advantage demonstrated in recently released data from a Phase III trial in squamous cell lung cancer.Keywords: immunotherapy, immunoncology, cancer, checkpoint inhibitorsGonzález-Cao MKarachaliou NViteri SMorales-Espinosa DTeixidó CSánchez Ruiz JMolina-Vila MÁSantarpia MRosell RDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol 2015, Iss default, Pp 55-70 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 González-Cao M Karachaliou N Viteri S Morales-Espinosa D Teixidó C Sánchez Ruiz J Molina-Vila MÁ Santarpia M Rosell R Targeting PD-1/PD-L1 in lung cancer: current perspectives
description	María González-Cao,1 Niki Karachaliou,1 Santiago Viteri,1 Daniela Morales-Espinosa,1 Cristina Teixidó,2 Jesús Sánchez Ruiz,3 Miquel Ángel Molina-Vila,2 Mariacarmela Santarpia,4 Rafael Rosell1,2,5,61Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain; 2Pangaea Biotech SL, Barcelona, Spain; 3Centro Nacional de Investigación Oncología (CNIO), Madrid, Spain; 4Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy; 5Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain; 6Fundación Molecular Oncology Research, Barcelona, SpainAbstract: Increased understanding of tumor immunology has led to the development of effective immunotherapy treatments. One of the most important advances in this field has been due to pharmacological design of antibodies against immune checkpoint inhibitors. Anti-PD-1/PD-L1 antibodies are currently in advanced phases of clinical development for several tumors, including lung cancer. Results from Phase I–III trials with anti-PD-1/PD-L1 antibodies in non-small-cell lung cancer have demonstrated response rates of around 20% (range, 16%–50%). More importantly, responses are long-lasting (median duration of response, 18 months) and fast (50% of responses are detected at time of first tumor evaluation) with very low grade 3–4 toxicity (less than 5%). Recently, the anti-PD-1 antibody pembrolizumab received US Food and Drug Administration (FDA) breakthrough therapy designation for treatment of non-small-cell lung cancer, supported by data from a Phase Ib trial. Another anti-PD-1 antibody, nivolumab, has also been approved for lung cancer based on survival advantage demonstrated in recently released data from a Phase III trial in squamous cell lung cancer.Keywords: immunotherapy, immunoncology, cancer, checkpoint inhibitors
format	article
author	González-Cao M Karachaliou N Viteri S Morales-Espinosa D Teixidó C Sánchez Ruiz J Molina-Vila MÁ Santarpia M Rosell R
author_facet	González-Cao M Karachaliou N Viteri S Morales-Espinosa D Teixidó C Sánchez Ruiz J Molina-Vila MÁ Santarpia M Rosell R
author_sort	González-Cao M
title	Targeting PD-1/PD-L1 in lung cancer: current perspectives
title_short	Targeting PD-1/PD-L1 in lung cancer: current perspectives
title_full	Targeting PD-1/PD-L1 in lung cancer: current perspectives
title_fullStr	Targeting PD-1/PD-L1 in lung cancer: current perspectives
title_full_unstemmed	Targeting PD-1/PD-L1 in lung cancer: current perspectives
title_sort	targeting pd-1/pd-l1 in lung cancer: current perspectives
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/53cb1147aa7d460ab1939a5683d7eba4
work_keys_str_mv	AT gonzaacutelezcaom targetingpd1pdl1inlungcancercurrentperspectives AT karachalioun targetingpd1pdl1inlungcancercurrentperspectives AT viteris targetingpd1pdl1inlungcancercurrentperspectives AT moralesespinosad targetingpd1pdl1inlungcancercurrentperspectives AT teixidoacutec targetingpd1pdl1inlungcancercurrentperspectives AT saacutenchezruizj targetingpd1pdl1inlungcancercurrentperspectives AT molinavilamaacute targetingpd1pdl1inlungcancercurrentperspectives AT santarpiam targetingpd1pdl1inlungcancercurrentperspectives AT rosellr targetingpd1pdl1inlungcancercurrentperspectives
_version_	1718402958105772032

Targeting PD-1/PD-L1 in lung cancer: current perspectives

Ejemplares similares